Objectives: To assess the efficacy of neoadjuvant chemotherapy (NAC) before radical cystectomy (RC) in a retrospective multicentre cohort of patients with cT2N0M0 bladder cancer (BCa) without preoperative hydronephrosis. Patients and Methods: This was a propensity-based analysis of 619 patients. Of these, 316 were treated with NAC followed by RC and 303 with upfront RC. After multiple imputations, inverse probability of treatment weighting (IPTW) was used to account for potential selection bias. Multivariable logistic regression analysis was performed to evaluate the impact of NAC on pathological complete response and downstaging at RC, while IPTW-adjusted Kaplan–Meier curves and Cox regression models were built to evaluate the impact of NAC on overall survival (OS). Results: After IPTW-adjusted analysis, standardised differences between groups were <15%. A complete response (pT0N0) at final pathology was achieved in 94 (30%) patients receiving NAC and nine (3%) undergoing upfront RC. Downstaging to non-muscle-invasive disease (

Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis

Soria F.
;
Gontero P.
2021-01-01

Abstract

Objectives: To assess the efficacy of neoadjuvant chemotherapy (NAC) before radical cystectomy (RC) in a retrospective multicentre cohort of patients with cT2N0M0 bladder cancer (BCa) without preoperative hydronephrosis. Patients and Methods: This was a propensity-based analysis of 619 patients. Of these, 316 were treated with NAC followed by RC and 303 with upfront RC. After multiple imputations, inverse probability of treatment weighting (IPTW) was used to account for potential selection bias. Multivariable logistic regression analysis was performed to evaluate the impact of NAC on pathological complete response and downstaging at RC, while IPTW-adjusted Kaplan–Meier curves and Cox regression models were built to evaluate the impact of NAC on overall survival (OS). Results: After IPTW-adjusted analysis, standardised differences between groups were <15%. A complete response (pT0N0) at final pathology was achieved in 94 (30%) patients receiving NAC and nine (3%) undergoing upfront RC. Downstaging to non-muscle-invasive disease (
2021
128
1
79
87
#BladderCancer; #blcsm; #uroonc; #utuc; bladder cancer; clinical T2; downstaging; hydronephrosis; neoadjuvant chemotherapy
Soria F.; Black P.C.; Fairey A.S.; Cookson M.S.; Yu E.Y.; Kassouf W.; Dall'Era M.A.; Sridhar S.S.; McGrath J.S.; Wright J.L.; Thorpe A.C.; Morgan T.M.; Daneshmand S.; Holzbeierlein J.M.; Bivalacqua T.J.; North S.; Barocas D.A.; Lotan Y.; Grivas P.; Stephenson A.J.; Shah J.B.; van Rhijn B.W.; Spiess P.E.; Shariat S.F.; Gontero P.
File in questo prodotto:
File Dimensione Formato  
bju.15289.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 597.71 kB
Formato Adobe PDF
597.71 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1783760
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 8
social impact